Platelet Activation Markers in Pediatric Cardiac Surgery

Effect of Cardiopulmonary Bypass on Platelet Activation Markers Such as Platelet Factor 4 and Transforming Growth Factor B, in Pediatric Cardiac Surgery

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00450151

Enrollment

Registered

2007-03-21

Start date

2007-02-28

Completion date

2009-02-28

Last updated

2012-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease

Keywords

Pediatric, Cardiopulmonary bypass Surgery, Cardiac Surgery, Platelet, Platelet Activation Markers, Platelet Factor4, Transforming Growth Factor Beta

Brief summary

In this study the focus will be on correlating the levels of platelet activation markers (proteins that are released when blood cells are activated)to the duration of cardiopulmonary bypass, temperature during cardiopulmonary bypass and the weight of the patient.

Detailed description

This research is being done because we would like to learn more about platelet dysfunction in children undergoing cardiopulmonary bypass. It has been an established fact that cardiopulmonary bypass causes dysfunction in platelets. Activation of platelets during cardiopulmonary bypass is implicated as being a major factor in causing platelet dysfunction. For all participants, approximately 3.15 ml of blood will be collected in special tubes called CTAD tubes, before and after cardiopulmonary bypass (6.30ml in total). This amount of blood draw is well within the guidelines of NIH (National Institute of Health). Enzyme-linked immunosorbent assay (ELISA) will be performed using this plasma to make quantitative assessment of Platelet factor 4 and Transforming growth factor beta.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 7 Years

Healthy volunteers

Inclusion criteria

* Patients scheduled to have surgery involving cardiopulmonary bypass for congenital cardiac abnormalities. * Age: Newborn to 7 years * Gender: male and female

Exclusion criteria

* Emergency surgery * Weight less than 3 kg * Age greater than 7 years * Patients with low platelet counts (\<100,000) * Patients on medications that are known to interfere with platelet function such as prostacyclins, non-steroidal anti-inflammatory drugs, plavix. Patients whose parents not willing to give consent

Countries

United States

Outcome results